Literature DB >> 21330406

Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements.

Mesfin Gonit1, Juan Zhang, Marcela d'Alincourt Salazar, Hongjuan Cui, Aymen Shatnawi, Robert Trumbly, Manohar Ratnam.   

Abstract

A need for androgen response elements (AREs) for androgen receptor (AR)-dependent growth of hormone depletion-insensitive prostate cancer is generally presumed. In such cells, androgen-independent activation by AR of certain genes has been attributed to selective increases in basal associations of AR with putative enhancers. We examined the importance of AR binding to DNA in prostate cancer cells in which proliferation in the absence of hormone was profoundly (∼ 90%) dependent on endogenous AR and where the receptor was not up-regulated or mutated but was predominantly nuclear. Here, ARE-mediated promoter activation and the binding of AR to a known ARE in the chromatin remained entirely androgen dependent, and the cells showed an androgen-responsive gene expression profile with an unaltered sensitivity to androgen dose. In the same cells, a different set of genes primarily enriched for cell division functions was activated by AR independently of hormone and significantly overlapped the signature gene overexpression profile of hormone ablation-insensitive clinical tumors. After knockdown of endogenous AR, hormone depletion-insensitive cell proliferation and AR apoprotein-dependent gene expression were rescued by an AR mutant that was unable to bind to ARE but that could transactivate through a well-established AR tethering protein. Hormone depletion-insensitive AR binding sites in the chromatin were functional, binding, and responding to both the wild-type and the mutant AR and lacked enrichment for canonical or noncanonical ARE half-sites. Therefore, a potentially diverse set of ARE-independent mechanisms of AR interactions with target genes must underlie truly hormone depletion-insensitive gene regulation and proliferation in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330406      PMCID: PMC3063083          DOI: 10.1210/me.2010-0409

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  55 in total

Review 1.  The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.

Authors:  Joanne Edwards; John M S Bartlett
Journal:  BJU Int       Date:  2005-06       Impact factor: 5.588

2.  Integrative molecular concept modeling of prostate cancer progression.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Xuhong Cao; Lei Wang; Saravana M Dhanasekaran; Shanker Kalyana-Sundaram; John T Wei; Mark A Rubin; Kenneth J Pienta; Rajal B Shah; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2006-12-17       Impact factor: 38.330

3.  Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.

Authors:  Scott M Dehm; Donald J Tindall
Journal:  J Biol Chem       Date:  2006-07-25       Impact factor: 5.157

4.  Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor.

Authors:  Nishit K Mukhopadhyay; Angeline S Ferdinand; Lipi Mukhopadhyay; Bekir Cinar; Mohini Lutchman; Jerome P Richie; Michael R Freeman; Brian C-S Liu
Journal:  Exp Cell Res       Date:  2006-07-28       Impact factor: 3.905

5.  R5020 and RU486 act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism.

Authors:  Aymen Shatnawi; Thuyet Tran; Manohar Ratnam
Journal:  Mol Endocrinol       Date:  2006-12-27

6.  Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.

Authors:  Youyuan Xu; Shao-Yong Chen; Kenneth N Ross; Steven P Balk
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

Review 7.  Molecular biology of prostate-cancer pathogenesis.

Authors:  Randi L Shand; Edward P Gelmann
Journal:  Curr Opin Urol       Date:  2006-05       Impact factor: 2.309

8.  Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene.

Authors:  Spiros Vlahopoulos; Warren E Zimmer; Guido Jenster; Narasimhaswamy S Belaguli; Steven P Balk; Albert O Brinkmann; Rainer B Lanz; Vassilis C Zoumpourlis; Robert J Schwartz
Journal:  J Biol Chem       Date:  2004-12-28       Impact factor: 5.157

9.  The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response.

Authors:  G Verrijdt; T Tanner; U Moehren; L Callewaert; A Haelens; F Claessens
Journal:  Biochem Soc Trans       Date:  2006-12       Impact factor: 5.407

10.  A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells.

Authors:  Tzu-Huey Li; Hongjuan Zhao; Yue Peng; Jason Beliakoff; James D Brooks; Zijie Sun
Journal:  Nucleic Acids Res       Date:  2007-04-10       Impact factor: 16.971

View more
  15 in total

1.  The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells.

Authors:  Min Shen; Zhen Zhang; Manohar Ratnam; Q Ping Dou
Journal:  J Cell Physiol       Date:  2014-06       Impact factor: 6.384

2.  Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation.

Authors:  Aritro Sen; Ismary De Castro; Donald B Defranco; Fang-Ming Deng; Jonathan Melamed; Payel Kapur; Ganesh V Raj; Randall Rossi; Stephen R Hammes
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

3.  Identification of ELK1 interacting peptide segments in the androgen receptor.

Authors:  Claire Soave; Charles Ducker; Seongho Kim; Thomas Strahl; Rayna Rosati; Yanfang Huang; Peter E Shaw; Manohar Ratnam
Journal:  Biochem J       Date:  2022-07-29       Impact factor: 3.766

4.  The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.

Authors:  Mugdha Patki; Venkatesh Chari; Suneethi Sivakumaran; Mesfin Gonit; Robert Trumbly; Manohar Ratnam
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

5.  Deregulation of an imprinted gene network in prostate cancer.

Authors:  Teodora Ribarska; Wolfgang Goering; Johanna Droop; Klaus-Marius Bastian; Marc Ingenwerth; Wolfgang A Schulz
Journal:  Epigenetics       Date:  2014-02-10       Impact factor: 4.528

6.  Identification of Androgen Receptor Modulators in a Prostate Cancer Cell Line Microarray Compendium.

Authors:  John P Rooney; Brian Chorley; Nicole Kleinstreuer; J Christopher Corton
Journal:  Toxicol Sci       Date:  2018-11-01       Impact factor: 4.849

7.  Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.

Authors:  Rayna Rosati; Lisa Polin; Charles Ducker; Jing Li; Xun Bao; Dakshnamurthy Selvakumar; Seongho Kim; Besa Xhabija; Martha Larsen; Thomas McFall; Yanfang Huang; Benjamin L Kidder; Andrew Fribley; Janice Saxton; Hiroki Kakuta; Peter Shaw; Manohar Ratnam
Journal:  Clin Cancer Res       Date:  2018-09-05       Impact factor: 12.531

8.  The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells.

Authors:  Javid A Dar; Khalid Z Masoodi; Kurtis Eisermann; Sudhir Isharwal; Junkui Ai; Laura E Pascal; Joel B Nelson; Zhou Wang
Journal:  J Steroid Biochem Mol Biol       Date:  2014-03-22       Impact factor: 4.292

Review 9.  Androgen receptor (AR) pathophysiological roles in androgen-related diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: lessons learned from mice lacking AR in specific cells.

Authors:  Chawnshang Chang; Shuyuan Yeh; Soo Ok Lee; Ta-Min Chang
Journal:  Nucl Recept Signal       Date:  2013-08-19

10.  Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.

Authors:  Hongjuan Zhao; Alan Thong; Rosalie Nolley; Stephen W Reese; Jennifer Santos; Alexandre Ingels; Donna M Peehl
Journal:  J Transl Med       Date:  2013-08-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.